Skip to content

Human Papillomavirus (HPV) Self-Sampling Options to Promote Equity

Human Papillomavirus Self-Sampling Options to Promote Equity (HOPE)

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07214506
Acronym
HOPE
Enrollment
100
Registered
2025-10-09
Start date
2026-08-01
Completion date
2027-05-31
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV Testing, Pap Smear, Uterine Cervical Neoplasms

Keywords

Cervical cancer screening, HPV self-collection, HPV test, Mobile health unit, Unhoused individuals, Community outreach

Brief summary

This study is testing a new way to help people who are unhoused get screened for cervical cancer. Cervical cancer can often be prevented if it is found early. Many people who lack stable housing usually do not receive regular screenings. Through this project, the investigators will bring screening to community locations in Tucson, Arizona, using a mobile health unit (MHU) from the University of Arizona (UA) and El Rio Health. At these sites, participants will receive easy-to-understand education about cervical cancer, learn how to collect their own sample for human papillomavirus (HPV) testing, and get follow-up care if needed. The study has two goals: * First, the investigators will see if this community-based approach helps more people complete cervical cancer screening. * Second, the investigators will ask participants, clinicians, and outreach staff for their opinions about the program and its practicality and acceptability. By testing this approach, the investigators hope to find a way to make cervical cancer screening more accessible and effective for unhoused individuals.

Detailed description

Cervical cancer can often be prevented if it is found early, but many unhoused people don't get regular screening. Through this project, the investigators are offering cervical cancer screening in community settings, such as our mobile health units, to make access easier. Our proposal aims to design and pilot test an human papillomavirus (HPV) self-sampling program run through an MHU (operated by the UA) throughout El Rio's established outreach sites to people who are unhoused and residing in shelters and outdoor encampments. The proposed intervention, delivered through a clinic-community linkage, will include tailored education about the importance of cervical cancer screening, information on how to perform HPV self-collection, and follow-up as needed. The investigators propose the following Aims: Aim 1. In a pragmatic pilot trial, assess the preliminary effectiveness of a community-driven, resource-efficient MHU-delivered program to distribute HPV DNA self-collection test kits to eligible unhoused individuals in Tucson, Arizona. The primary outcome will be the completion of screening among eligible individuals. Secondary outcomes will be (1) screening modality selected (self-collected HPV, clinician-collected HPV, Pap smear, or co-test) and (2) follow-up of abnormal initial screening results within 6 months after the initial result. Aim 2. Evaluate the feasibility and acceptability of the MHU-based HPV self-collection program through in-depth interviews with individuals who completed self-collection, clinicians, and outreach staff in the HOPE program. Interview domains will be informed by the COM-B (capability, opportunities, motivation - behavior) framework, and outcomes will be analyzed using thematic analysis with a combination of inductive and deductive coding.

Interventions

OTHERHuman papillomavirus Self-collection

The individual will receive both verbal instruction on self-collection from trained health educators in the mobile health unit, as well as adapted educational materials on human papillomavirus self-collection and information about follow-up care in the case of abnormal results. Individuals will be provided with a safe and private space in the Mobile Health Unit to self-collect.

OTHERUsual Care

Usual care, will involve reminders about overdue Cervical Cancer screening and support with scheduling clinic appointments for screening, arranging for transportation, and addressing other barriers to attendance

Sponsors

University of Arizona
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
El Rio Santa Cruz Neighborhood Health Center
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

The proposed trial will randomize eight of the street medicine team's outreach sites 1:1 to either the intervention (invitation to Human Papillomavirus self-collection for cervical cancer screening in the mobile health unit plus usual care from the street medicine team) or usual care alone

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* Women or transgender men with a cervix * Ages 30-64 years * Due for cervical cancer screening: 1. No Pap test in the past 3 years, or 2. No human papillomavirus (HPV) test in the past 5 years * Unhoused or unstably housed

Exclusion criteria

* History of cervical cancer * HIV positive * History of total hysterectomy * Known pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Cervical Cancer Screening CompletionFrom enrollment to the end of treatment at 8 weeksCervical cancer screening completion will be defined as the completion of any form of cervical cancer screening permitted according to the U.S. Preventive Services Task Force (USPSTF) guidelines, including Pap tests, Pap tests with high-risk human papillomavirus tests (cotesting), or high-risk human papillomavirus testing alone. The primary outcome will be assessed within 2 months of the street medicine team's patient contact during the trial period to account for the time required for scheduling a clinic appointment.

Secondary

MeasureTime frameDescription
Follow-up adherenceFrom identification of abnormal results to 6 monthsThe secondary outcome will be follow-up adherence for abnormal screening results ascertained via electronic health record review within six months of the abnormal result

Countries

United States

Contacts

CONTACTPurnima Madhivanan, MBBS, MPH, PhD
pmadhivanan@arizona.edu520-621-5730
CONTACTRogelio Robles, MD
rroblesmd@arizona.edu520 245 5844
PRINCIPAL_INVESTIGATORDan Theodorescu, MD, PhD

University of Arizona

STUDY_CHAIRPurnima Madhivanan, MBBS, MPH, PhD

University of Arizona

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026